-

Hims & Hers to Participate in Canaccord Genuity's Virtual eCommerce Sustainable Advantage Forum on March 14, 2024

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that members of the company’s management team will be participating in Canaccord Genuity's Virtual eCommerce Sustainable Advantage Forum on March 14, 2024. All events will be webcast live and archived on the Hims & Hers investor relations website at https://investors.forhims.com.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.hims.com/.

Contacts

Investor Relations
Bill Newby
Investors@forhims.com

Media Relations
Abby Reisinger
Press@forhims.com

Hims & Hers Health, Inc.

NYSE:HIMS

Release Versions

Contacts

Investor Relations
Bill Newby
Investors@forhims.com

Media Relations
Abby Reisinger
Press@forhims.com

More News From Hims & Hers Health, Inc.

Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, an...

Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making...

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD. GLP-1 treatments have transformed obesity and metabolic health, with...
Back to Newsroom